Autopsy report · NCT02290119

Gait and Functional Improvement in Total Knee Arthroplasty With the Use of Verasense for Soft Tissue Balancing

“as a result of Orthosensor's acquisition by Stryker in July 2018.No final mutually agreed (signed) protocol was found and no clear records of the study data can be retrieved. No accurate and reliable results of this study can be posted.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 5 months before it started.
• Ran for about 4 years 6 months before it stopped.
• 20 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Orthosensor, Inc.

Sponsor type

Industry

Conditions

Osteoarthritis

Interventions

Sensor-assisted TKR (Verasense); Control - Without the use of Verasense

Participants

20

Sites

1

Countries

United States

Trials that died the same way

• Tritanium® Primary Acetabular Shell Study
  “As longitudinal patient follow-up continues to lag, Stryker has determined that the study is no longer able to meet the regulatory requirements this study intends to support. Termination is not related to any safety concerns with the products.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.